Rivaroxaban submitted for wider approval in EU

04/12/2012 | Fox Business

Bayer is seeking EU authorization to market anti-coagulant rivaroxaban as a pulmonary embolism therapy. Partner Johnson & Johnson will apply this quarter for FDA approval of rivaroxaban to treat venous thromboembolism, a Bayer spokeswoman said.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC